# 🧬 CGT 每日情报 (Daily Brief)
> **日期**: 2026-02-07 | **更新时间**: 09:19 (北京时间)
> **监控范围**: Global (In vivo/FDA) & China (NMPA/Biotech)

---

## 🌍 全球前沿 (FDA / In vivo / MNCs)
- `[21:30]` **🏛️监管 | FDA 批准 Kite 的 Yescarta® 治疗复发/难治性原发性中枢神经系统淋巴瘤的标签更新**
  <br><small>🇬🇧 *FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma* [🔗Source](https://news.google.com/rss/articles/CBMi9wFBVV95cUxOZmtzNDYzdjFxcmpKZHF1aU11YTNwM1pLdU1yV2p1cUVQQXJ6ZzItN0hfMmMwZFFnRW9LekhublJzUk5tTjZLaTlKaUNQUng1VkV6cEtZQzFlR2xaZjFzZEU4Y00tQXo2MHkxTTFPRnZXZ3d0UVMzQlM0cnFFR0psaHVWMUloMURHOC1ScHZ4N1ZLcnk3X3FTQmFTd3dTd1hLanlvaHdTSThpaVRIRkhCaFN1VGEyZVY4U2NjanFoVWxncUVDMUE0bldxQ0lHb2R6MDJZeUY5ZlloUGFZaGFSMWJxTWJHNnVXYnhFYkVYR1pBcWN1Tmxn?oc=5)</small>
- `[13:13]` **🏛️监管 | Everest Medicines 宣布中国 NMPA 批准 VELSIPITY ®用于成人中重度活动性溃疡性结肠炎**
  <br><small>🇬🇧 *Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis* [🔗Source](https://news.google.com/rss/articles/CBMilAJBVV95cUxOTFJMQ2tfLV8zNC1RbkpBNkRSQXJ3dlVydi0xM0JxYmVqUXkzQXBZOTVnMXlBdWpLN2o3NC1YTFowem9vZ3FsX2RFeEg0WmdwaTZiS0N0b0RhcVBSLXNPWTZVNWthRXM2bXpFQjEzbjhMVVZwWjByaUFQT1Zaend2Mlc4YVlHbkRpcW94cUlpMW1mX3pINTZzR0tqUDF0RHFfaHE2bWFDNjl3MUJpY0tXZ1hsRDMtVlRzRnZFT0pZV25fc3hYcFVpLUVXaUl1dXM0YUFpbVRZcDZBcDFNeFBCVlRsSHRpWUpkTHQtSFBCanNOMTZQel9WZEREQ2paOUNkYVNRMWxWSjUwQXg1V0pYOTBjVks?oc=5)</small>

---

## 🇨🇳 中国动态 (NMPA / Domestic Players)
- `[23:31]` **Varnim-cel CAR-T疗法：B细胞恶性肿瘤患者的新希望？全面解读临床疗效与安全性** [🔗阅读原文](https://news.google.com/rss/articles/CBMiRkFVX3lxTFBCLTNncjZ0Y3NFaXlxWVB6MlY4QWt5Y0VnMG9CY0RDS2x3ajdGcjVDbXJ6bUVvZzAyMlhqVjl6QkdCVWRyS3c?oc=5)
- `[16:38]` **TRX103细胞疗法：HLA不匹配造血干细胞移植后的新希望？最新临床研究揭示其安全性和潜力** [🔗阅读原文](https://news.google.com/rss/articles/CBMiRkFVX3lxTE42eVVlejZDMTVrSlRXdGpBaG1sSmtRWWVJMnRhc3R3OXo2SUxua2lsRDVxUW5SQUZTZHhhM0FkQ2hqOG1zcnc?oc=5)
- `[15:30]` **CDE新政出台！细胞治疗药品药学变更有了明确指导原则，行业规范化再迈新台阶** [🔗阅读原文](https://news.google.com/rss/articles/CBMifkFVX3lxTFBpWURET1NMelpGZXJ4Q3VaRGpvYXJlTFl5UTcxTXNMRERtZUJlREhWaDRkN0prMG9IMmdIRVB5VmJnZU9GY2VWY2N1TGJaX2NFUXhqLUVjdjd4NC12M3o1MTAxNTlUMjZNVlc2SzZodUFMNkdyTGxndkJGeGFzUQ?oc=5)
- `[13:47]` **🏛️监管 | Everest Medicines 宣布中国 NMPA 批准 VELSIPITY ®用于成人中重度活动性溃疡性结肠炎**
  <br><small>🇬🇧 *Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis* [🔗Source](https://news.google.com/rss/articles/CBMi9AFBVV95cUxQbG1UTGttUmE0aFk1TjhYS2Z1TjZaV3VrV3ZJcjRVdzBwQ21jeHJlaFp0WnJEemw1dnFjaUtOUlQ0b1BzR1FycU1oUXVjLXV2OUJfd0tfZmVfXzlKQlRLZHd5WG91V2FoTmdOMGNEUXY3elAwUEJIeXZ5amVGb0RYOUZfb3ZPbUJFZloya1FVc1p1MDByeFFGU3V0ZHNlLS1ybFpBUmxnM0ktbFpFUFV1VENSM0sxZTNQUkozX0FWRWNwVUFtZ2IzNm1PV2VyTzRxVVhJRlRqR0VtQXFwQUdHbThJUzJ4YWhUcFg4R3pCbDdRUHVG?oc=5)</small>
